INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number		10554408			
Filing Date		2006-11-30			
First Named Inventor	Leand	Leander Grode et al			
Art Unit		1645			
Examiner Name	Rodn	ey P. Swartz			
Attorney Docket Number		2923-737			

					U.S.	PATENTS				
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue D	ate	Name of Pat of cited Docu	entee or Applicant ument	nt Pages,Columns,Lines w Relevant Passages or R Figures Appear		
	1	6673353	B1	2004-01	-06	Kaufmann et a	la			
If you wisl	n to ac	ld additional U.S. Pate	nt citatio	n inform	ation pl	ease click the	Add button.			
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS			
Examiner Initial*		No Publication Number	Kind Code ¹			Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1									
If you wisl	n to ad	ld additional U.S. Pub	lished Ap	•		·		butto	n.	
				FOREIG	SN PAT	ENT DOCUM	IENTS			,
Examiner Initial*				Country Code ² j		Publication Date	Name of Patentee or Applicant of cited Document		Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	т5
	1 2001514000		JP		т	2001-09-11				
If you wish	n to ad	d additional Foreign F	atent Do	cument	citation	information p	lease click the Add	buttor	1	
			NON	I-PATEN	IT LITE	RATURE DO	CUMENTS			
Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where publisher.									T5	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		10554408			
Filing Date		2006-11-30			
First Named Inventor	Leand	der Grode et al			
Art Unit		1645			
Examiner Name	Rodney P. Swartz				
Attorney Docket Number		2923-737			

	1	rode et al., "Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette- uerin mutants that secrete listeriolysin", THE JOURNAL OF CLINICAL INVESTIGATION, vol. 115, no. 9, Septembe	. 0				
	2	ones et al., "Characterization of Listeria monocytogenes Pathogenesis in a Strain Expressing Perfringolysin O in ace of Listeriolysin O in Place of Listeriolysin O", INFECTION AND IMMUNITY, Dec. 1994, p. 5608-5613.					
	3	ortnoy et al., "Capacity of Listeriolysin O, Streptolysin O, and Perfringolysin O to Mediate Growth of Bacillus subtilis thin Mammailan Cells, INFECTION AND IMMUNITY, Vol. 60, No. 7, July 1992, p. 2710-2717.					
	4	nsho to biselbutsu (Clinic and Microbes), 1997, vol. 24, no. 1, pgs. 37-43.					
	5	ambrook et al., Molecular Cloning, A laboratory Manual. Cold Spring Harbor Laboratory Press (1989), 1.101-1.104.					
	6	Sambrook & Russell, Molecular Cloning, A Laboratory Manual, 3rd edition, (2001) Vol. 2, 10.47, formula (3).					
If you wis	h to a	additional non-patent literature document citation information please click the Add button					
		EXAMINER SIGNATURE					
Examiner Signature Date Considered							

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.